Testing blood samples for DNA repair gene changes in metastatic prostate cancer
Studies a new testing method using blood samples in adults with metastatic prostate cancer.
Plain-language title generated from the registry record
Registry title: Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- European Institute of OncologyMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT06762379
- Record updated
- 15 September 2026
- Original description
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integrationRead full original descriptionShow less
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
Inclusion: Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Exclusion: Unable to provide written informed consent.